GVS
870976
Hangzhou CNCR-IT
300250
Shanghai Newtouch Software
688590
4
Ucap Cloud Information Technology Co.,Ltd
688228
5
Yangtze Optical Electronic
688143
US Stock MarketDetailed Quotes
IMRX Immuneering
- 2.157
- +0.007+0.34%
Trading Jan 24 10:34 ET
66.99MMarket Cap-1.10P/E (TTM)
2.200High2.120Low98.80KVolume2.120Open2.150Pre Close212.80KTurnover0.44%Turnover RatioLossP/E (Static)31.05MShares7.68052wk High1.16P/B48.32MFloat Cap1.00052wk Low--Dividend TTM22.40MShs Float33.990Historical High--Div YieldTTM3.72%Amplitude1.000Historical Low2.153Avg Price1Lot Size
Trending Stocks
Discussing
U.S.-China talks spark interest, no more inflation?
🎙️Discussion: 1. How will Trump's China policies affect Chinese assets? 2. Which sectors might benefit as U.S. inflation risks decline?
Moomoo News Global
Dec 9, 2024 20:23
China Will Adopt a "Moderately Accommodative" Monetary Policy in the Next Year, The First Shift to Easing Since 2011
Immuneering Stock Forum
I will buy 100 more shares when it hits $2.25
IMM-1-104
Further IMM-1-104 Phase 2a data expected in the second quarter of 2025
Initiation of Phase 2a arms of IMM-1-104 in combination with a BRAF inhibitor, as well as IMM-1-104 in combination with a checkpoint inhibitor, planned for 2025
Immuneering's Cancer Drug Shows 50% Response Rate in Phase 2a Pancreatic Cancer Trial, Beating Benchmark
On January 13, 2025, Immuneering Corporation (the "Company") announced updated interim response and safety data from the ongoing Phase 2a arm evaluating IMM-1-104 with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients, part of the Company's ongoing Phase 1/2a clinical trial of IMM-1-104 in patients with advanced RAS-mutant solid tumors.
The Company announced that, as of January 6, 2025, of the six evaluable patients in the ...
Anyone understands why the stock price keep dropping despite of the positive news?!!!
The rapid progression of IMM-1-104's development program is noteworthy. Having two parallel first-line pancreatic cancer combination arms showing comparable response rates strengthens the drug's potential positioning. The planned expansion into BRAF inhibitor and checkpoint inhibitor combinations in 2025 suggests a comprehensive development strategy targeting multiple therapeutic approaches.
The Q2 2025 data update will be crucial, as it wil...
Immuneering Provides Positive Update on Phase 2a Arm Studying Imm-1-104 in Combination With Modified Folfirinox for First-Line Pancreatic Cancer
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
Monday, 13th January at 8:00 am
- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer -
- Overall Response Rate (ORR) of 50%; historic benchmark of 32% for FOLFIRINOX alone -
- Nearly $14M in net proceeds raised in January 20...
No comment yet